Opinion

Video

ImBRAVE 050 Study Results and Discussion Around Who is a High-Risk Patient

Panelists discuss findings from the IMmbrave050 trial comparing atezolizumab plus bevacizumab to active surveillance in patients with high-risk hepatocellular carcinoma patients, highlighting the significance of follow-up for those at risk of recurrence post- curative treatment.

Video content above is prompted by the following:

Dr Li: Please discuss the IMmBRAVEbrave050 trial evaluating atezolizumab +plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinomaHCC. (Yopp A, ESMO Congress 2024, LBA39).
• Please comment on:
o• the Iimportance or non-importance of follow-up for patients who are at high risk of recurrence after receiving curative-intent resection or ablation with curative intent.

Related Videos
Related Content